Retrospective study of monoclonal gammopathies detected in the clinical laboratory of a Spanish healthcare district: 14-Year series

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 2, 2007, Pages 190-196

  Bergón, Enrique ^a   Miravalles, Elena ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Classification of monoclonal gammopathies; Incidence; M protein isotype distribution; Prevalence

Indexed keywords

AGAROSE; CELLULOSE ACETATE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; ISOPROTEIN; M PROTEIN;

ADULT; AGED; ANAMNESIS; ARTICLE; B LYMPHOCYTE; CAPILLARY ZONE ELECTROPHORESIS; CLINICAL FEATURE; CLINICAL LABORATORY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ELECTROPHORESIS; FEMALE; HEALTH CARE FACILITY; HUMAN; LIGHT CHAIN; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PREVALENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; SPAIN; TIME SERIES ANALYSIS; WORLD HEALTH ORGANIZATION;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CLINICAL LABORATORY TECHNIQUES; DELIVERY OF HEALTH CARE; FEMALE; HUMANS; IMMUNOGLOBULIN ISOTYPES; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYELOMA PROTEINS; PARAPROTEINEMIAS; RETROSPECTIVE STUDIES; SPAIN;

EID: 33847096457     PISSN: 14346621     EISSN: 14346621     Source Type: Journal    
DOI: 10.1515/CCLM.2007.029     Document Type: Article

References (23)

1. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
2. Ong F, Hermans J, Noordijk EM, Kieviet W, Wijermans PW, Seelen PJ, et al. Developing a population-based registry for patients with paraproteinemias or multiple myeloma. J Clin Epidemiol 1997;50:909-15.
3. Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) in 6995 sera from adult population. Acta Med Scand 1966;179:235-47.
4. Kyle RA. Monoclonal gammopathy of undetermined significance and solitary plasmacytoma. Hematol Oncol Clin North Am 1997;1:74-87.
5. Bergón Jiménez E, García Alonso L. Frecuencia de gammapatías monoclonales en una muestra no seleccionada. Quím Clín 1997;16:29-32.
6. Ögmundsdóttir HM, Haraldsdóttir VV, Jóhannesson GM, Ólafsdóttir G, Bjarnadóttir K, Sigvaldason H, et al. Monoclonal gammopathy in Iceland: a population-based registry and follow-up. Br J Haematol 2002;118:166-73.
7. Phekoo KJ, Schey SA, Richards MA, Bevan DH, Bell S, Gillett D, et al. A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK. Br J Haematol 2004;127:299-304.
8. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, Tahri N, Elloumi M, Baklouti S, et al. Gammapàthies monoclonales en Tunisie: analyse épidé miologique, immunochimique et étiologique d'une série de 288 cas. Pathol Biol 2005;53:19-25.
9. Memoria 1999-2000 del Área Sanitaria 10. Madrid: Insalud, 2001.
10. Bergón E, Miravalles E, Bergón E, Miranda I, Bergón M. The predictive power of serum κ/λ ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma. Clin Chem Lab Med 2005;43:32-7.
11. Bergón Jiménez E, Bergón Sendín M. Uso del cociente cadenas kappa/cadenas lambda en orina para el estudio de la proteína de Bence Jones. Quim Clin 1999;18:266-70.
12. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray Ch, Lozano R, Inoue M. Age standardization of rates: a new WHO standard. http://w3.whosea.org/healthreport/ pdf/paper31.pdf.
13. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Public-Use, Nov 2004 Sub (1973-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006. http://seer.cancer.gov/seerstat/ WebHelp/Rate_Algorithms.htm.
14. Landgren O, Gridley G, Turesson I, Caporaso NE, Goldin LR, Baris D, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 2006;107:904-6.
15. Bowden M, Crawford J, Cohen HJ, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly. J Am Geriatr Soc 1993;41:11-4.
16. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol 1982;35:63-8.
17. Bergón Jiménez, E. Bergón Sendín M. Transferibilidad de resultados entre procedimientos electroforéticos para la valoración de un componente monoclonal. Quím Clin 1998;17:227-31.
18. Bergón E, Miranda I, Miravalles E. Linearity and detection limit in the measurement of serum M-protein with the capillary zone electrophoresis system Capillarys®. Clin Chem Lab Med 2005;43:721-3.
19. Surveillance, Epidemiology, and End Results (SEER) Program Populations (1969-2003) (www.seer.cancer.gov/popdata), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2006. http://seer.cancer.gov/statfacts/htlm/mulmy_print.htlm
20. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance: a review. Immunol Rev 2003;194:112-39.
21. Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece. Ann Hematol 2002;81:357-61.
22. Gregersen H, Mellemkjær L, Ibsen JS, Dahlerup JF, Thomassen L, Sørensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica 2001;86:1172-9.
23. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol 2002;20:1625-34.